Описание
Rosuvastatin increases warfarin plasma concentrations through inhibition of CYP2C9, potentially leading to supratherapeutic INR values.
Механизм
Rosuvastatin inhibits CYP2C9, the principal enzyme for S-warfarin metabolism, resulting in reduced clearance and elevated warfarin levels.
Клиническое значение
INR increases of approximately 10–20% have been observed in pharmacokinetic studies; clinically significant bleeding has been reported.
Тактика ведения
Monitor INR when initiating or adjusting rosuvastatin dose; the FDA label specifically warns about this interaction.
Медицинский отказ от ответственности
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.